Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Cost of RevenueGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Guided Therapeutics (GTHP) Short-Term Debt issuances (2020 - 2022)

Guided Therapeutics recorded quarterly Short-Term Debt issuances of -$90000.0 in Q1 2022, down 69.81% quarter-over-quarter from -$53000.0 in Q4 2021, and up 83.84% year-over-year from -$48955.1 in Q1 2021.

Guided Therapeutics' Short-Term Debt issuances history runs 3 years deep, the most recent figure standing at -$90000.0 for Q1 2022.

  • In Q1 2022, Short-Term Debt issuances rose 83.84% year-over-year to -$90000.0; the TTM figure through Mar 2022 stood at -$842000.0 (changed N/A YoY), while the FY2021 annual figure was -$1.5 million, down 33.33% from the prior year.
  • Short-Term Debt issuances came in at -$90000.0 for Q1 2022 at Guided Therapeutics, down from -$53000.0 in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of -$53000.0 in Q4 2021 to a low of -$557000.0 in Q1 2021.
  • A 3-year average of -$210500.0 and a median of -$116000.0 in 2020 frame the typical range for Short-Term Debt issuances.
  • Across the five-year window, Short-Term Debt issuances soared 62.68% in 2021 and soared 83.84% in 2022, its largest moves.
  • Guided Therapeutics' Short-Term Debt issuances stood at -$142000.0 in 2020, then jumped by 62.68% to -$53000.0 in 2021, then slumped by 69.81% to -$90000.0 in 2022.
  • According to Business Quant data, Short-Term Debt issuances over the past three periods registered -$90000.0, -$53000.0, and -$557000.0 for Q1 2022, Q4 2021, and Q1 2021 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 31.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -1.23 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -1.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 37.80 Mn
10 Guided Therapeutics - - 458,000.00 -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2022 -90,000.00
Mar 31, 2022 -90,000.00
Dec 31, 2021 -53,000.00
Dec 31, 2021 -53,000.00
Mar 31, 2021 -557,000.00
Mar 31, 2021 -557,000.00
Dec 31, 2020 -142,000.00
Dec 31, 2020 -142,000.00